Race Initiates FTO-Directed Kidney Cancer Preclinical Study
Race Initiates FTO-Directed Kidney Cancer Preclinical Study
Race Oncology Limited (“Race”) is pleased to announce that it has entered into a new collaborative preclinical research program with The University of Newcastle. The work will be led by eminent cancer researcher, Associate...
Race Initiates FTO Melanoma Preclinical Study
Race Initiates FTO Melanoma Preclinical Study
19 March 2021 – Race Oncology Limited (“Race”) is pleased to announce that it has entered into a collaborative preclinical research program with The University of Newcastle. Eminent melanoma cancer researchers, Professor Xu Dong...
Compelling Preclinical Breast Cancer Results
Compelling Preclinical Breast Cancer Results
Race Oncology Limited (ASX: RAC) is pleased to share the final results of our collaborative preclinical research program with the eminent cancer researcher, Associate Professor Nikki Verrills of The University of Newcastle and Hunter...
Positive Early Preclinical Ovarian Cancer Results
Positive Early Preclinical Ovarian Cancer Results
Race Oncology Limited (ASX: RAC) is pleased to share further interim results of our continuing collaborative preclinical research program with The University of Newcastle. Eminent cancer researcher, Associate Professor Nikki Verrills of the Hunter...
Mary Harney appointed Non-Executive Director of Race
Mary Harney appointed Non-Executive Director of Race
Race Oncology Limited (Race or the Company) (ASX: RAC) is pleased to announce that Ms Mary Harney has been appointed Non-Executive Director. An accomplished NED and Chief Executive, Ms Harney brings deep understanding of...
‘Three Pillar’ Strategic Update
‘Three Pillar’ Strategic Update
Race Oncology is pleased to release our updated strategic plan for the clinical advancement of Bisantrene at our 2020 AGM. The recent identification of Bisantrene as a potent inhibitor of the Fat and obesity...
Impressive Preclinical Bisantrene Breast Cancer Results
Impressive Preclinical Bisantrene Breast Cancer Results
Race Oncology Limited (ASX: RAC) is pleased to share results of the collaborative preclinical research program between Race and The University of Newcastle. Eminent cancer researcher, Associate Professor Nikki Verrills of the Hunter Medical...
Phase 2 Bisantrene trial data published in European Journal of Haematology
Phase 2 Bisantrene trial data published in European Journal of Haematology
10 November 2020 – Race Oncology Limited (ASX: RAC) is pleased to report that the clinical data from the investigator initiated Phase II clinical trial of Bisantrene in relapsed and refractory Acute Myeloid Leukaemia...
Phase II Bisantrene trial data to be presented at ASH 2020
Phase II Bisantrene trial data to be presented at ASH 2020
5 November 2020 – Race Oncology Limited (ASX: RAC) is pleased to report that the clinical data from the investigator initiated Phase II clinical trial of Bisantrene in relapsed and refractory Acute Myeloid Leukaemia...
Prof. Borje S. Andersson appointed Chief Medical Officer
Prof. Borje S. Andersson appointed Chief Medical Officer
Race Oncology Limited is pleased to announce that Professor Borje S. Andersson has agreed to join Race as Chief Medical Officer and Executive Director. Under this role, Prof. Andersson will be responsible for progressing...
